Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.59 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.59 |
| ▸ | REN | P00797 | 2/20 | 0.58 |
| ▸ | NTSR2 | O95665 | 7/20 | 0.57 |
| ▸ | NTSR1 | P30989 | 7/20 | 0.57 |
| ▸ | SORT1 | Q99523 | 6/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30445678 | 1.00 | SLC6A2 (0.60) | SLC6A2AGTR2AGTR1RENNTSR2 | |
| SCHEMBL30446840 | 0.95 | NTSR2 (0.54) | AGTR2AGTR1NTSR2NTSR1SORT1 | |
| SCHEMBL30446282 | 0.95 | NTSR2 (0.54) | AGTR2AGTR1NTSR2NTSR1SORT1 | |
| SCHEMBL30445757 | 0.92 | SLC6A2 (0.62) | SLC6A2REN | |
| SCHEMBL29416554 | 0.92 | SLC6A2 (0.64) | SLC6A2REN | |
| SCHEMBL28659771 | 0.88 | OPRM1 (0.68) | SLC6A2 | |
| SCHEMBL28659786 | 0.88 | OPRM1 (0.68) | SLC6A2 | |
| SCHEMBL29571594 | 0.87 | NTSR1 (0.62) | NTSR2NTSR1SORT1 | |
| SCHEMBL29531376 | 0.87 | SLC6A2 (0.72) | SLC6A2 | |
| SCHEMBL29530548 | 0.87 | SLC6A2 (0.72) | SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110506105-B | Novel bacterium belonging to the genus Bifidobacterium | 森永乳业株式会社 | 2023-03-24 | — | — | CN | claimed |
| CN-115244401-A | DPP3 for therapy guidance, monitoring and stratification of NT-ADM antibodies in shock patients | 4TEEN4制药有限公司 | 2022-10-25 | — | — | CN | claimed |
| CN-119630969-A | DPP3 increase in patients predicted to suffer from septic shock | 4TEEN4制药有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119604526-A | Anti-Adrenomedullin (ADM) antibodies or anti-ADM antibody fragments or anti-ADM non-Ig scaffolds for the treatment or prevention of shock | 艾德里诺医药公司 | 2025-03-11 | — | — | CN | disclosed |
| US-12178838-B2 | Synthetic neuromodulatory peptides | LACTOCORE, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| CN-115997814-B | Preparation method of A2 beta-casein pediatric milk | 广州迪卡德营养科技有限公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-119072492-A | Stable aqueous formulations of anti-Adrenomedullin (ADM) antibodies or anti-ADM antibody fragments | 艾德里诺医药公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-113573723-B | Synthetic neuromodulatory peptides | 拉托科公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
| CN-117660420-B | Microbacterium chymosin and application thereof | 山东省农业科学院 | 2024-07-02 | — | — | CN | disclosed |
| US-12013392-B2 | Global proteomic screening of random bead arrays using mass spectrometry imaging | AMBERGEN, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| EP-4133280-A1 | PREDICTION AND EARLY DIAGNOSIS OF ACUTE KIDNEY INJURY | Sciomics GmbH (DE) | 2023-02-15 | — | — | EP | disclosed |
| CN-114544540-B | Rapid batch detection method for A2 type beta casein content in milk | 华中农业大学 | 2022-11-29 | — | — | CN | disclosed |
| CN-115244081-A | anti-Adrenomedullin (ADM) binding agents for the treatment of patients with shock | 艾德里诺医药公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115244080-A | anti-Adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for the treatment or prevention of shock | 艾德里诺医药公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115244401-A | DPP3 for therapy guidance, monitoring and stratification of NT-ADM antibodies in shock patients | 4TEEN4制药有限公司 | 2022-10-25 | — | — | CN | disclosed |
| US-20220175873-A1 | SYNTHETIC NEUROMODULATORY PEPTIDES | LACTOCORE, INC. | 2022-06-09 | — | — | US | disclosed |
| CN-114556100-A | Therapy guidance and/or therapy monitoring for treatment of shock | 4TEEN4制药有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-114544540-A | Rapid batch detection method for A2 type beta casein content in milk | 华中农业大学 | 2022-05-27 | — | — | CN | disclosed |
| US-11285165-B2 | Selective high-affinity polydentate ligands and methods of making such | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2022-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11285165-B2 | Selective high-affinity polydentate ligands and methods of making such | CD44, FCGR3B, FCGR2A | SLC6A2 1606/4885AGTR2 2467/4885AGTR1 2599/4885 |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | SLC6A2 3925/4885AGTR2 100/4885AGTR1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.